GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Short-Term Debt

MESO (Mesoblast) Short-Term Debt : $13.86 Mil (As of Jun. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Mesoblast Short-Term Debt?

Mesoblast's Short-Term Debt for the quarter that ended in Jun. 2024 was $13.86 Mil.

Mesoblast's quarterly Short-Term Debt declined from Dec. 2023 ($8.53 Mil) to Mar. 2024 ($0.00 Mil) but then increased from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($13.86 Mil).

Mesoblast's annual Short-Term Debt increased from Jun. 2022 ($5.02 Mil) to Jun. 2023 ($5.95 Mil) and increased from Jun. 2023 ($5.95 Mil) to Jun. 2024 ($13.86 Mil).


Mesoblast Short-Term Debt Historical Data

The historical data trend for Mesoblast's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Short-Term Debt Chart

Mesoblast Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.46 53.20 5.02 5.95 13.86

Mesoblast Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 8.53 - 13.86 -

Mesoblast Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Mesoblast Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Mesoblast's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast Business Description

Traded in Other Exchanges
Address
55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.